GeneMatrix Inc.

A109820

KR7109820001

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-06-27 EDT			5-day change	1st Jan Change
2,490 ^KRW	-1.19%		-5.14%	-19.81%

2023	GeneMatrix Inc.(KOSDAQ:A109820) dropped from S&P Global BMI Index	CI
2021	GeneMatrix Inc.(KOSDAQ:A109820) added to S&P Global BMI Index	CI

GeneMatrix Inc. announced that it has received KRW 3.5 billion in funding

February 08, 2018

On February 9, 2018, GeneMatrix Inc. (KOSDAQ:A109820) closed the transaction.

Latest news about GeneMatrix Inc.

GeneMatrix Inc.(KOSDAQ:A109820) dropped from S&P Global BMI Index	23-09-18	CI
GeneMatrix Inc.(KOSDAQ:A109820) added to S&P Global BMI Index	21-09-20	CI
Vaccitech Limited announced that it has received £6 million in funding from GeneMatrix Inc., Korea Investment Partners Co. Ltd.	18-12-19	CI
GeneMatrix Inc. announced that it has received KRW 6.99999647 billion in funding from Korea Investment Partners Co. Ltd.	18-12-12	CI
GeneMatrix Inc. announced that it expects to receive KRW 6.99999647 billion in funding from Korea Investment Partners Co. Ltd.	18-12-04	CI
GeneMatrix Inc. announced that it has received KRW 3.5 billion in funding	18-02-08	CI
GeneMatrix Inc. announced that it has received KRW 6.5 billion in funding	18-01-29	CI
GeneMatrix Inc. announced that it expects to receive KRW 3.5 billion in funding	18-01-28	CI
GeneMatrix Inc. announced that it expects to receive KRW 6.5 billion in funding	18-01-28	CI
GeneMatrix Inc. announced that it has received KRW 5 billion in funding from KB Investment Co., Ltd., ID Ventures, POSCO Venture Capital Co., Ltd..	15-07-26	CI
GeneMatrix Inc. announced that it expects to receive KRW 5 billion in funding from KB Investment Co., Ltd., ID Ventures, POSCO Venture Capital Co., Ltd..	15-07-23	CI
GeneMatrix Inc.'s Equity Buyback announced on January 27, 2011 has expired.	14-07-26	CI
Tranche Update on GeneMatrix Inc.'s Equity Buyback Plan announced on January 27, 2011.	14-07-24	CI
GeneMatrix Inc.'s Equity Buyback Plan Extended till July 26, 2014.	14-01-23	CI
GeneMatrix Inc.'s Equity Buyback Plan Extended till January 26, 2014	13-07-19	CI
GeneMatrix Inc.'s Equity Buyback Plan Extended till July 27, 2013	13-01-24	CI
GeneMatrix Inc.'s Equity Buyback Plan Extended till January 2013.	12-07-26	CI
GeneMatrix Inc.'s Equity Buyback Plan Extended till July 26, 2012.	12-01-25	CI

GENEMATRIX Inc. is a Korea-based company mainly engaged in biotechnology business. The Company operates in two segments: pharmaceutical development and diagnostic medicine. Its pharmaceutical development segment specializes in the development of restriction fragment mass polymorphism (RFMP) genotyping technology for diagnosis of hepatitis B virus (HBV), hepatitis C virus (HCV), human papillomavirus (HPV) and others. Its diagnostic medicine segment specializes in the manufacture and sale of liver-function examination reagents, and import and sale of medical equipment and reagents.

Sector

Biotechnology & Medical Research

Calendar

2024-08-13 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GENEMATRIX INC.	-19.81%	37.07M
LONZA GROUP AG	+38.65%	39.1B
IQVIA HOLDINGS INC.	-8.62%	38.76B
ALNYLAM PHARMACEUTICALS, INC.	+26.95%	31.24B
ICON PUBLIC LIMITED COMPANY	+10.74%	25.9B
CELLTRION, INC.	-13.50%	25.8B
UNITED THERAPEUTICS CORPORATION	+44.87%	14.06B
MEDPACE HOLDINGS, INC.	+34.36%	13.12B
BIO-TECHNE CORPORATION	-7.14%	11.32B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-12.61%	10.68B

Other Biotechnology & Medical Research

GeneMatrix Inc.

Equities

A109820

KR7109820001

Biotechnology & Medical Research

GeneMatrix Inc. announced that it has received KRW 3.5 billion in funding

Latest news about GeneMatrix Inc.

Chart GeneMatrix Inc.

Company Profile

Sector Other Biotechnology & Medical Research